https://www.selleckchem.com/pr....oducts/GSK690693.htm
e subsequent hospitalizations, a factor that could contribute to poorer future health for people with severe LD. In addition to chronic conditions prevalent in this study population, we found new diagnoses in the 5-year post-LD period including acute renal failure. With LD incidence increasing, more research is needed to understand conditions and factors that influence long term health after LD. To analyze the short-term therapeutic efficacy of intravitreal injection of bevacizumab (IV for chronic central serous chorioretinopathy (C
Curtir
Comentario
Compartilhar
